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Estimating the health burden 
of aflatoxin attributable 
stunting among children in low 
income countries of Africa
Hifza Rasheed1,2, Ya Xu3, Martin E. Kimanya4, Xiaoxi Pan3, Zhihua Li5, Xiaobo Zou5, 
Candida P. Shirima6, Melvin Holmes1, Michael N. Routledge3,5* & Yun Yun Gong1*
Numerous population-based studies have documented high prevalence of aflatoxin associated 
childhood stunting in low income countries. We provide an estimate of the disease burden of aflatoxin 
related stunting using data from the four African countries. For this empirical analysis, we obtained 
blood aflatoxin albumin adduct biomarker based exposure data as measured using ELISA technique 
and anthropometric measurement data from surveys done over a 12-year period from 2001 to 2012 in 
four low income countries in Africa. We used these data to calculate population attributable risk (PAR), 
life time disease burden for children under five by comparing two groups of stunted children using 
both prevalence and incidence-based approaches. We combined prevalence estimates with a disability 
weight, measuring childhood stunting and co-occurrence of stunting-underweight to produce years 
lived with disability. Using a previously reported mortality, years of life lost were estimated. We 
used probabilistic analysis to model these associations to estimate the disability-adjusted life-years 
(DALYs), and compared these with those given by the Institute for Health Metrics and Evaluation’s 
Global Burden of Disease (GBD) 2016 study. The PAR increased from 3 to 36% for aflatoxin-related 
stunting and 14–50% for co-occurrence of stunting and underweight. Using prevalence-based 
approach, children with aflatoxin related stunting resulted in 48,965.20 (95% uncertainty interval 
(UI): 45,868.75–52,207.53) DALYs per 100,000 individuals. Children with co-occurrence of stunting 
and underweight due to exposure to aflatoxin resulted in 40,703.41 (95% UI: 38,041.57–43,517.89) 
DALYs per 100,000 individuals. Uncertainty analysis revealed that reducing aflatoxin exposure in high 
exposure areas upto non-detectable levels could save the stunting DALYs up to 50%. The burden of 
childhood all causes stunting is greater in countries with higher aflatoxin exposure such as Benin. In 
high exposure areas, these results might help guide research protocols and prioritisation efforts and 
focus aflatoxin exposure reduction. HEFCE Global Challenge Research Fund Aflatoxin project.
Childhood stunting is considered as a main consequence of poor nutrition and multiple exposures (social and 
environmental etc.) affecting one-third of children under 5 and is responsible for about 15% of under 5 mortal-
ity  worldwide1,2. Impaired child growth as a result of nutrient deficiencies, recurrent infections, exposure to 
fecal–oral contamination and environmental toxins poses an increased risk of morbidity and mortality from 
infectious diseases and impaired mental  development3. As of 2013, more than half of all stunted children under 
5 lived in Asia (56%) and more than one third lived in Africa (38%)4. Despite several programmes launched to 
prevent malnutrition, the global and regional child malnutrition estimates of the United Nations Children Edu-
cation  Funds4 from 2000 to 2016 revealed minor improvement in reducing child stunting in South Asia (38 to 
24%) and Africa (38 to 31%). These are the regions of low and middle income countries (LMIC), where growth 
faltering has not been entirely explained by inadequate nutrition alone, whilst foodborne aflatoxin exposure 
especially through staple food such as maize and groundnuts is also more  prevalent5. The dietary exposure to 
aflatoxin, a family of mycotoxins mainly produced by Aspergillus flavus, Aspergillus parasiticus and Aspergillus 
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nomius had placed approximately 4.5 billion people at health risk in the developing countries due to aflatoxin 
induced liver cancer, childhood stunting, acute aflatoxicosis and modulation of the immune  system6–8.
The most common analogs of aflatoxin found in food are aflatoxin B1 (AFB1), aflatoxin B2 (AFB2), afla-
toxin G1 (AFG1), and aflatoxin G2 (AFG2), with AFB1 being the most highly toxic  compound9. The major 
reactive metabolite of AFB1 in the human body i.e. exo-AFB1 8,9-epoxide, which if not detoxified, can bind 
to double-stranded DNA to form the promutagenic AFB1-N7-guanine adduct or, following hydrolysis to the 
AFB1- dihydrodiol, with proteins such as  albumin10,11. Though childhood stunting in LMICs is a multifactorial 
process, a growing body of scientific evidences has highlighted an association between aflatoxin exposure and 
childhood stunting. Both urinary AFB1-N7-guanine and serum AFB1-lys levels are associated with dietary 
intake of aflatoxin and are useful for estimating the AFB1  exposure12–14. Using the urinary biomarkers and/or 
serum aflatoxin-albumin (AF-alb) adducts, the link between wide spread exposure of aflatoxin in early life and 
child linear growth impairment have been shown in Benin and  Togo15,16,  Gambia17,18,  Tanzania19,  Nigeria20 and 
 Nepal21. These studies reported that aflatoxin exposure solely or under the influence of other risk factors affects 
the child growth. Pre-natal and neonatal exposure of aflatoxin have been demonstrated through Transplacental 
 transfer22–24, human breast  milk25,  weaning26 and post-weaning  foods16 reporting the contributory role of afla-
toxin exposure in child growth impairment and life-long implications.
The underlying mechanism for aflatoxin induced growth impairment so far discovered are related to its 
immune modulation, reduced insulin like growth factor 1 (IGF-1), and aflatoxin-induced  enteropathy27–29. 
Mupunga et al.30 had reported the interference of aflatoxin with intestinal integrity and hepatic metabolism 
thus contributing in malabsorption, micronutrient deficiencies, impaired immune function, and vulnerability 
to gut infections, all of which may lead to impaired growth and malnutrition. Aflatoxin was also reported to 
modulate immune function in vitro and in  animals31. A small number of studies have also shown changes in 
immune function in  humans32. Similarly, aflatoxin with co-exposure of fumonisin and deoxynivalenol (DON) 
mediate intestinal damage leading to chronic systemic immune activation and malabsorption of nutrients, and 
consequently to growth  retardation33,34.
Apart from health damage caused by aflatoxin exposure, its socio-economic consequences are also crucial. 
Estimated economic loss may manifest in reduced learning capacity in school, chronic diseases in adulthood 
linked with compromised loss of working hours/days and lower earning potential and ultimately decreasing the 
quality of life. The Global Burden of Disease (GBD) Injuries and Risk Factors Study   201335 has estimated the 
burden of stunting attributable to various risks, however aflatoxin exposure is so far not included as a reason of 
childhood stunting probably due to data paucity. Considering the availability of empirical data on prevalence of 
exposure to aflatoxin from past studies, the present study has attempted to evaluate the link between aflatoxin 
exposure as mesaured using blood aflatoxin albumin adduct biomarker using ELISA technique  (references see 
Table 1) and socio-economic consequences by determining the burden of child stunting in terms of DALYs as 
a case study in African villages.
Study design and participants. The data used in this study originated from four previous studies on 
aflatoxin exposure assessment in different agro-ecological zones of western and eastern Sub-Sahara African 
countries, where maize and/or groundnut is predominantly produced with slight variation of harvest time. These 
prospective cohort studies or case–control studies were selected based on the well-defined sample sizes, afla-
toxin exposure or dose assessments, anthropometric measurement and appropriate multivariate analyses. A 
brief detail of the selected studies is tabulated as Table 1.
Considering stunting as an outcome, the study participants were characterised with respect to their stunting 
status as shown in Figs. 1, 2 and 3. The studies used questionnaire based interviews and 24-h dietary recall ques-
tionnaire to gather the information on child age, sex, birth weight, breast feeding, weaning age, HBV vaccination, 
Table 1.  Studies included in the analysis of disease burden. *Infants born between May 2011 and December 
2012 from the Early Nutrition and Immune Development (ENID, ISRCTN49285450) trial were recruited for 
an aflatoxin exposure assessment.
Author, year Country Study design Study area
Study 
recruitment dates






No. of follow 
up visits






2001 16–37 (months); 3rd 200 49 3
Gong et al. (2002); 
Gong et al. (2003)
15,26
Benin and Togo Cross-sectional study
16 villages (30/








2010–11 5–13 (months):3rd 166 52 3
Watson et al. 
(2017)*18 The Gambia Cohort
West Kiang 
district of The 
Gambia*
2011–12 6 months: 3rd 374 49 3
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socioeconomic status, family size or dietary consumption in one or all of the studies. These data were used in  
the current analysis.  
To estimate the prevalence of stunting and number of stunted children under five, this study included the 
children of age 5 months to under five years at recruitment. Children recruited in all four studies have been 
followed for aflatoxin exposure by measuring aflatoxin albumin adducts in the blood sample using an ELISA 
method (see Table 2 for visit wise concentrations of AF-alb concentration) and anthropometric measurements 
over 1 or 3 time points during maize harvest and/or storage periods.
These studies measured anthropometric parameters such as body height and weight, weight-for-age (WAZ), 
height/length-for-age (HAZ, Fig. 1) and weight-for-height/length Z-scores (WHZ) were calculated at multiple 
times during follow-up in all cohorts. Applying 2006 WHO  Standards36 and the 1977 NCHS/WHO  Reference37, 
stunting prevalence was calculated and reflected as in Fig. 1.
The level of aflatoxin exposure and childhood stunting in above listed four studies also indicated a consist-
ent relationship between aflatoxin exposure and childhood growth (Figs. 2 and 3) and possibility of biologically 
plausibility independent of and together with other risk factors.
The logistic regression analysis between levels of AF-alb (with log and without log) and stunting status (Yes/
No) was performed to see the relationship. Details of prerequisite tests for logistic regression (Supplementary 
material: Table 1S) revealed the significant association (p < 0.05) between stunting and AF-alb concentration. 
The DALYs for stunting and aflatoxin associated stunting were calculated, as described below.
Calculation of all causes and cause-specific DALYs for childhood stunting. DALYs are healthy life 
years lost, that combines the adjusted number of years lived with disability (YLDs) and the number of years of 
life lost due to premature mortality (YLLs)38 calculated using Eqs. (1) to (3).
Figure 1.  Prevalence of stunting (HAZ < − 2) in the selected study area with significant difference (P = 0.0005) 









































Figure 2.  Mean conc. of AF-alb (pg/mg albumin) in stunted and non-stunted populations.
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DALYs under five for all cause stunting was calculated based on data collected from the field visits for up to 
age under five. DALYs for all cause stunting were also calculated from a lifetime perspective based on age specific 
life expectancy of each country given by the Global burden of disease  study39.
Criteria used for calculation of YLL. The data of past  studies40–42 have revealed higher bio-availability of 
aflatoxin metabolites in children relative to their body weight resulting in their limited detoxification capacity for 
AFB1. Knipstein,  Huang31 have reported that growth hormone (GH) resistance occurs in children with aflatoxin 
induced chronic liver injury and thus GH-resistance is presented as a candidate mechanism by which AFB1 
might cause stunting. Consequently, stunted and/or underweight children were observed to be significantly at 
higher risk of dying from infectious diseases, increased health problems, cognitive impairments, lower school 
achievements, reduced life-time earnings, and decreased  productivity43,44. According to the findings of Briend 
et al.45 and Olofin et al.46 children with co-occurrence of stunting and underweight are considered at higher risk 
with increased hazards of death from diarrhoea, pneumonia, and measles with decreased Z scores. Likewise 
reported child fatalities due to AFB1 after 1–3 weeks exposure of 20 μg/kg BW/day47.
The study by Olofin et al.46 have determined the all-cause and cause-specific mortality hazard ratios (HR) in 
relation to child growth indicator ranged as 1.56 (0.98, 2.46) for HAZ (− 2 to < − 1) and 6.41(3.77, 10.89) for 
(1)DALYs = YLL + YLD
(2)No. of deaths due to stunting × Life Expectancy at age of death
(3)No. of stunting cases × mean duration of disease × disability weight
Figure 3.  Visit wise prevalence of stunting %age vs, conc. of AF-alb (pg/mg albumin).
Table 2.  AF-alb concentration (pg/mg albumin) levels in human sera in the study areas.
Country Overall detectable AF-alb (%)
1st Visit 2nd Visit 3rd visit
Mean ± SD Mean ± SD Mean ± SD
Benin 99 71.34 ± 94.30 66.15 ± 82.17 170.51 ± 219.44
Benin and Togo 100 62.60 ± 101.08 – –
Tanzania 91 9.52 ± 17.33 38.61 ± 61.28 39.25 ± 54.99
The Gambia 91 10.70 ± 60.91 54.07 ± 94.62 91.88 ± 130.13
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HAZ < − 3, whilst HR for Weight-for-Age Z score (WAZ) was 1.72 (1.08, 2.73) for WAZ (− 2 to < − 1) and 12.80 
(6.97, 23.49) for WAZ < − 3. Black et al.1  and48 had estimated the deaths attributable to nutritional disorders using 
statistics of deaths for under five by UN Interagency Group on Mortality Estimation and prevalence estimates 
from the UN and Nutrition Impact Model Study (NIMS). The estimates by Black et al.1 for mortality of stunted 
(14.7%), underweight (14.4%), and wasted children (12.6%) in LMICs also confirmed the previously calculated 
cause specific mortality estimates by Black et al.48, Pelletier et al.49, Caulfield et al.50 and Olofin et al.46. The calcu-
lations by Black et al.1 for mortality risk associated with stunting and wasting were the same using different data 
source such as UN or NIMS prevalence estimates. Moreover, about 36.6% of children under five were reported 
to be stunted in sub-Saharan Africa (SSA) in  201535. Compared to this high stunting prevalence, the mortality 
risk of stunting (age 1–4 years) reported in Global Disease Study  201651 were estimated to be 0.02%, 0.05%, 
0.06% and 0.05% for Togo, Gambia, Benin and Tanzania respectively. Since, the real time data produced from 
four selected aflatoxin studies (Table 1), children showed 23–69% of co-occurrence of stunting and underweight 
(Fig. 4) suggesting the possibility of higher mortality risk among stunted children. Thus, to avoid underestima-
tion, the association of mortality with HAZ and WAZ as reported by Olofin et al.46 and respective mortality 
rates (14.7%) and (14.4%) reported by Black et al.1 was used to establish the assumptions for YLL calculation.
Three different models were computed for modelling the burden of stunting in these countries. Model-1 
was based on the number of stunting cases (HAZ < − 2SD) compared to non-stunted children in all popu-
lations, Model-2 considered the number of children at co-occurrence of stunting and underweight (HAZ & 
WAZ < − 2SD) compared to those without this co-occurrence, whilst Model-3 took into account the children at 
co-occurrence of stunting-underweight (HAZ & WAZ < − 2SD) compared to remaining all children without this 
co-occurrence i.e. either stunted or under-weight or healthy children.
Criteria used for calculation of YLD. Victora et  al.52 reported that stunting is especially difficult to 
reverse after 36 months of age, whilst the Lancet nutrition series estimated that the nutrition-specific interven-
tions together, if scaled up to 90%, would reduce the prevalence of stunting by only about 20%3. Similarly, Sve-
fors et al.53 reported that children stunted at 4.5 years usually remain stunted at 5 years and later. According to 
International Food Policy Research  Institute54 dietary aflatoxin exposure in the intervention group would need 
to be reduced by at least 35% for a detectable impact on child growth. Considering these findings, we have also 
assumed the possible effects of interventions such as nutritional supplements and aflatoxin exposure reduction 
to reverse the stunting within first 36 months of age by 20% thus saving the disability-adjusted life years (DALYs) 
in the sub-Sahara African countries. Considering this, we have calculated DALYs taking into account the YLL 
and YLD for up to 5 years based on strictly empirical data and from a lifetime perspective.
For the stunted children, YLDs were calculated as the sum of months the children had been stunted or 
stunted and underweight from birth to third/last visit in each study (i.e., they had a HAZ and/or HAZ &WAZ 
below -2 from the WHO reference median) times a disability weight of 0.002 recommended by the World Health 
 Organization55. Based on the under-five mortality rates as reported by Black et al.1, their YLLs were calculated as 
number of deaths due to stunting (Model-1)/stunted and underweight (Model-2 & 3) times age, sex and country 
specific life expectancy at age of death provided by global burden of diseases  study39.
Of the remaining 85.3% of the stunted children (Model-1) or 85.6% of the stunted and underweight chil-
dren (Model-2 & 3), there is a probability of recovery of 20% of the mild and moderately stunted (HAZ < − 2) 
or stunted and underweight children (HAZ & WAZ < − 2) if interventions for nutrition, disease prevention 
and aflatoxin exposure reduction provided. Whilst, children who were stunted or had co-occurrence (stunted 
Figure 4.  Prevalence of stunting, underweight and co-occurrence of both in study participants.
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and under-weight children) at third visit were assumed to be stunted at 5 years and were assumed to carry over 
this stunting or co-occurrence throughout life. The remaining of the stunted (65.3%) or stunted and underweight 
children (65.6%) were assumed to remain stunted throughout the life and their YLDs were calculated from a 
lifetime perspective based on age and sex specific life expectancy.
A disability weight is a weight factor that reflects the severity of the disease on a scale from 0 (perfect health) 
to 1 (equivalent to death).The disability weight attributed to stunting by the global burden of disease study was 
0.002 and is used in this study and reflecting the severity of a disease or condition of 0.002 on a 0–1  scale55. Age 
weighting and discount rates (social weighting) were not used in this study, in line with the 2010 GBD  study56.
Population attributable risk (PAR). We calculated the AF-alb adjusted relative risk (RR) of stunting per 
unit change in AF-alb for 3 models. RR is calculated by dividing the incidence rate among those exposed to the 
high concentration of AF-alb (upper tertile of AF-alb) by the incidence rate among those exposed to the low 
concentration of AF-alb (lower tertile). AF-alb adjusted RRs of three models were used to calculate population 
attributable risk (PAR) using Eq. (4)57.
where pi is the prevalence of exposure level i, RR is the relative risk of disease in exposure level i of AF-alb, and k 
is the total number of exposure levels. The PAR were then applied to the DALYs calculated for aflatoxin induced 
stunting. The estimated PAR quantifies the independent effect of aflatoxin on stunting (holding all other risk 
factors of stunting such as health status, nutritional intake, food quality, poor sanitation, and general poverty 
as constant).
Sensitivity analysis. Using the probabilistic approach all YLL, YLD and DALY calculations are presented 
with 95% uncertainty intervals (95%UI) calculated using the @RISK software package, Version 7.5 (2018 Pali-
sade Corp. USA)58. This included a 10,000-trial Monte Carlo simulation with all inputs varied simultaneously. 
To quantify uncertainty, we took ± 10% variation of these parameters i.e. YLL, YLD, DALY, PAR (%), thus gen-
erating 95th percentiles. To generate the 95% UI, these parameters were assumed to be normally distributed. 
However, following the GBD’s uncertainty principle in the absence of data and a method that would allow one 
to estimate the correlation of uncertainty between YLLs and YLDs, we also assumed that, for estimating DALYs, 
YLL and YLD uncertainty distributions were independent.
Results
Study population. There were 1220 children altogether enrolled in the four studies. Subjected to the avail-
ability of anthropometry record and concentration of AF-alb of 1145 children, comparison of three groups i.e. 
children with stunting, children with no stunting and those at co-occurrence of stunting and underweight is 
(4)PAR =
∑k
i=1 pi(RRi − 1)
∑k
i=0 pi(RRi − 1)+ 1
Table 3.  Distribution of level of AF-alb concentration (pg/mg albumin) with respect to stunted and non-
stunted cases. *Overall population is total population is 1220, HAZ score of 75 could not be available, hence 
analysis is performed for 1145 participants.
Study *Total study population
Children with stunting (HAZ < − 2)
Children at co-occurrence (HAZ and 








Tanzania 146 82 56.2 52.06 (23.31–80.81) 19 13.0 31.57 (13.24–49.91) 63 43.2 40.01 (27.15–52.867)
Gambia 350 76 21.7 88.11 (67.03–109.18) 45 12.9 76.88 (57.19–96.56) 272 77.7 91.95 (74.48–109.41)
Benin & Togo 456 149 33.0 88.00 (65.28–110.73) 92 20.2 106.69 (72.49–140.90) 306 67.0 48.08 (41.09–55.15)
Benin 193 76 39.4 229.95 (175.02–284.87) 53 28.0 250.48 (182.94–318.01) 115 59.6 130.15 (94.634–165.66)
Overall 1145 383 33.5 109.41 (92.04–126.77) 209 18.3 132.37 (106.31–158.43) 756 66.0 75.01 (66.04–83.97)
Table 4.  Population attributable risk percent (PAR%) calculated for three risk models.
Country
Model-1 Model-2 Model-3
PAR% (95% UI) for HAZ < − 2 PAR% (95% UI) for HAZ & WAZ < − 2
Remaining all including either stunted OR 
underweight OR normal)
Tanzania 3.04 (2.78–3.30) 14.29 (13.05–15.53) 15.16 (13.83–16.48)
Gambia 23.44 (21.41–25.48) 27.26 (24.91–29.61) 27.25 (24.90–29.62)
Benin & Togo 23.35 (21.33–25.38) 30.70 (28.04–33.38) 33.52 (30.64–36.45)
Benin 35.69 (32.58–38.77) 49.79 (45.51–54.10) 52.62 (48.08–57.20)
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given at Table 3. Overall the children with stunting (109.41 pg/mg) and those at co-occurrence of stunting and 
underweight (132.27 pg/mg) showed higher AF-alb concentration compared to those found without stunting 
(75.01 pg/mg). Stunted children in Benin study and in Benin and Togo study showed a higher aflatoxin exposure 
in all cases. Moreover, the significant association (p > 0.05) between AF-alb and stunting (supplementary mate-
rial: Table 1S) also convinced us to estimate DALYs.
RR > 1 for the three models denotes a larger incidence in the exposed than in the non-exposed indicating that 
exposure to the factor (AF-alb conc.) seems to increase the probability of developing the stunting (Supplementary 
Information: Figure-1S). The PAR% of all the three models was highest for the study population of Benin and 
lowest for Tanzania subjected to the AF-alb concentration (Table 4).
YLLs, YLDs and DALYs of all causes stunting. The output measures as YLL, YLD and DALYs calculated 
from a lifetime perspective for models 1 and 2, are presented with 95% uncertainty intervals (95%UI) in Tables 4 
and 5. The total burden of all cause stunting (model-1) was highest in Tanzania with DALYs of 366,118.51 (95% 
UI: 342,672.97, 389,353.08) followed by 279,297.50 (95% UI: 261,792.06, 296,843.87) DALYs in Benin. Whilst, 
stunting due to aflatoxin exposure caused loss of 3–36% of DALYs, highest in Benin such as 99,693.32 (95% 
UI: 89,271.91, 110,617.71) DALYs per 100,000 people followed by 47,783.70 (95% UI: 42,762.95,53,029.93) per 
100,000 people in Benin & Togo study (Table 5).
DALYs per 100,000 people from all cause co-occurrence (stunting and underweight) was 176,663.83 (95% 
UI: 165,280.40–187,900.65) highest in Benin followed by 130,499.25 (95% UI: 122,302.17–138,858.37) in Benin 
& Togo. With similar pattern, aflatoxin exposure also caused 87,963.94 (95% UI: 78,457.86–97,815.26) DALYs 
lost due to co-occurrence (stunting and underweight) in Benin (Table 6).
In model-3, children with co-occurrence of stunting and under-weight in the four studies were compared with 
remaining all children. The difference of YLDs, YLLs and DALYs between model-3 and model-2 is negligible 
i.e. 176,558.47 (95% UI: 165,298.76–188,016.46) all cause DALYs lost in Benin followed by 130,543.71 (95% UI: 
122,369.89–138,750.59) in Benin & Togo participants. Similar trend was found for aflatoxin induced DALYs with 
no considerable difference between results of models 2 (Table 6) and 3 (Supplementary information: Table 2S).
Children with stunting only (model-1) have shown comparatively higher all causes stunting DALYs with dif-
ference of 25% (Tanzania), 50% (Gambia), 64% (Benin and Togo), 63% (Benin) than children at co-occurrence of 
stunting and underweight (model-2) (Tables 5 & 6). Whereas, Aflatoxin induced DALYs difference between mod-
els-1 and 2 ranges between 58 to 88%. There is not much difference between DALYs of models 2 and 3. The total 
burden of aflatoxin caused stunting using 3 models was estimated at 48,965.20 (95% UI: 45,868.75–52,207.53) 
(model-1), 40,703.41 (95% UI: 38,041.57–43,517.89) (model-2) and 43,072.67 (95% UI: 40,164.58–46,054.89) 
(model-3) per 100,000 population.
Changing the mean (baseline) input values for YLLs and YLDs by 10–50%, the standard error on the mean 
for these samples analysed led to a change up to 70% for the mean output DALYs (Fig. 5).
Table 5.  YLLs, YLDs and DALYs of stunted children.
MODEL-1
All causes stunting Aflatoxin induced DALYs per 100,000 
(95% UI)YLD (95% UI) YLL (95% UI) DALYs (95% UI) All DALYs per 100,000 (95% UI)
Tanzania 6.23 (5.83, 6.63) 527.92 (493.50–561.93) 534.15 (499.82–568.15) 366,118.51 (342,672.97–389,353.08) 11,143.48 (9937.60–12,388.47)
Gambia 6.07 (5.69, 6.46) 549.19 (513.80–584.25) 555.26 (519.90–590.30) 159,051.70 (148,925.49 -169,141.44) 37,283.05 (33,345.64–41,338.40)
Benin + Togo 11.45 (10.72,12.17) 917.28 (859.24–975.43) 928.73 (870.64–986.95) 204,631.51 (191,829.06–217,471.17) 47,783.70 (42,762.95–53,029.93)
Benin 5.91 (5.53, 6.28) 532.41 (498.72–566.26) 538.31 (504.62–572.13) 279,297.50 (261,792.06–296,843.87) 99,693.32 (89,271.91–110,617.71)
Overall 29.65 (28.65, 30.64) 2526.39 (2442.62–2609.54) 2556.05 (2472.29–2639.21) 252,252.45 (243,853.94–260,600.65) 48,965.20 (45,868.75–52,207.53)
Table 6.  YLLs, YLDs and DALYs of children with co-occurrence of stunting and under-weight.
Model 2
DALYs Relative to the existing number of stunting cases DALYs per 100,000 
(95%UI)
AFB-1 DALYs per 
100,000 (95%UI)YLD (95%UI) YLL (95%UI) DALYs (95%UI)





Gambia 3.72 (3.48–3.96) 274.48 (256.97–292.14) 278.20 (260.71–295.86) 79,685.48 (74,680.81–84,739.76)
21,719.92 (19,444.06–
24,099.26)
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Discussion
Aflatoxin is a known human liver carcinogen classified by the IARC 9. The WHO has reported the health burden 
of aflatoxin based on its  carcinogenicity59. More recently, increasing evidence supports that aflatoxin may con-
tribute to child stunting  adversely31,60,61. Owning to the complexity in the causation of child stunting, adverse 
effect on child stunting by aflatoxin is not easily defined or clearly quantified. It became more widely recognised 
that nutrition specific intervention has not reduced child stunting as effectively as expected. Nutrition sensitive 
approaches extending effects to environment, food system and societal aspects are being promoted in tackling 
child malnutrition. In this regard, it is timely to include common hazards in the population such as aflatoxin 
in the intervention package. Characterising aflatoxin impact on child stunting has become an urgent matter. 
Following this, the current study has estimated the burden of stunting among children under five (age up to 
45 months at third visit) that may be attributable to aflatoxin exposure in four African countries. The Global 
Burden of Disease (GBD), Injuries, and Risk Factor study  201362 was the first of a series of annual updates with 
appropriate counterfactual risk distribution for six new risk factors including childhood stunting and  wasting62. 
However, aflatoxin as a cause of this risk factor (childhood stunting) has not been included in the last Global 
Burden of Disease Injuries, and Risk Factor  study35,51. Since several studies have provided the evidences of asso-
ciation between aflatoxin exposure and childhood stunting and bridged the data gap constraining the estimation 
of aflatoxin disease burden, this study is probably the first analysis that has attempted to use DALYs to measure 
the burden of stunting due to aflatoxin exposure in different African countries populations.
Our results suggest that 3–36% of stunting related DALYs in these populations is attributable to aflatoxin 
exposure. For children with both stunting and underweight, the contribution of aflatoxin exposure to lost DALYs 
within this sub set of children is larger (14–49%), although overall DALYs from co-occurrence is lower as this 
is a smaller sub set of children.
When comparing stunting burden by countries, the highest burden of stunting in different western and east-
ern Sub-Saharan African countries in this assessment is supported by previous prevalence  studies18,20 reporting 
high prevalence of aflatoxin exposure in areas of low income countries consuming maize and ground nuts as 
staple food, and where storage of these facilitates the aflatoxin exposure under warm climate. Consequently, the 
burden of aflatoxin caused possible stunting over the human lifespan has differing patterns in regions with high 
or low aflatoxin exposure. Benin was the country with higher prevalence of stunting (40%) and underweight 
(45%) with co-occurrence of both as 28%. The prevalence of stunting and underweight children in the Gambia 
(22% vs 20%), Benin and Togo studies (33% vs 29%) was closely matching, however in Tanzania the differ-
ence is high: 56.2% stunting vs 14.4% underweight and co-occurrence of both is only 13%. Moreover, AFB-1 
concentration and stunting prevalence in the third follow up visit compared to first and second visits forecasts 
the DALYs burdens to increase substantially during adulthood possibly due to increased exposure to aflatoxin 
through consumption of family food.
The disease burden of aflatoxin induced stunting estimated by models 1, 2 and 3 suggests that package of 
interventions such as nutritional interventions, health interventions, WASH interventions to reduce childhood 
stunting should also include the aflatoxin exposure reduction interventions with priority focus on stunted chil-
dren and those affected both by stunting and underweight.
The all causes stunting DALYs in this risk assessment when compared with the 2016 Global Burden of Dis-
eases (GBD) shows that various theoretical and methodological challenges may affect both the calculation and 
Figure 5.  Sensitivity Analysis of Aflatoxin caused Stunting DALYs (models 1, 2 & 3).
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interpretation of DALYs estimates. The countries included in the current study (Tanzania, Benin, Togo, Gambia) 
are in the GBD study  201639 list of countries without vital registration for 1980–2016. For such regions with 
missing health data, estimates are derived from other similar regions, and predictive covariates. For instance 
in Africa, many countries lack reliable cause specific mortality data and GBD modelling outputs may be over-
reliant on inherent  assumptions63. In GBD study (2016) stunting DALYs of four countries (9466.713 per 100,000 
populations) is lower than that estimated in this analysis (729,801.72 per 100,000 populations). This difference 
is due to a) difference of stunting related mortality rates as in GBD,  201635,51 stunting linked mortality rates of 
0.02%, 0.05%, 0.06% and 0.05% for Togo, Gambia, Benin and Tanzania respectively were used which resulted 
in GBD assumption that stunting has very low mortality (YLL) estimation, and; b) difference in age and gender 
specific life expectancy i.e. country specific life expectancy of 64–68 years used in this study whilst GBD  study39 
has used the maximum life expectancy of 82 years (female) and 84 years (male) for all the countries. Comparing 
the stunting burden by sex indicated no considerable difference of DALYs (data not shown).
Considering the availability of adequate AFB1 exposure data, the study outcomes suggest that the GBD 
analysis data on childhood stunting may also include impaired child growth due to aflatoxin exposure which 
is causally related to childhood stunting. Moreover, there is a consistency of the DALYs burden from stunting 
in GBD studies (2013 to 2016) and demands the availability of high-quality data on mortality due to stunting 
and aflatoxin induced stunting to enact local, national, and global change for stunting reduction especially for 
economically disadvantaged populations.
DALYs of men were found 1.5 times higher than the DALYs in women in this study and thus there was no 
considerable difference in terms of gender disparity due to lower difference of stunting prevalence (data not 
shown). However, there may be some factors which might have influenced this disease burden analysis and 
cannot be ignored as a source of uncertainty for future DALY’s estimation. These include lack of control group 
(unexposed to AFB1), breast feeding, wean age, birth weight, socioeconomic status, co-exposure of other myco-
toxins such as fumonisins and variation of time/season of  3rd visits in four countries, variation in crop harvest 
time of maize and/or ground nut. Holding all these as constant, a 10–50 folds increase in input parameters 
resulted in change in DALYs up to 70% from the mean.
Conclusions
We have analysed data from four studies that explored the association between aflatoxin exposure and child 
stunting. We found that aflatoxin exposure made a significant contribution to DALYs lost due to stunting, 
with an average of 16% of lost DALYs attributable to aflatoxin exposure. For children with both stunting and 
underweight, this figure was 34%. The regional heterogeneity observed in this study highlights the importance 
of understanding local burden of disease. The estimations provided in this study might help to address aflatoxin 
exposure and ultimately reduce its impact on the health of the African population.
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